Subcutaneous amivantamab with lazertinib is non-inferior to intravenous administration, with fewer adverse reactions
1. Subcutaneous amivantamab combined with lazertinib was non-inferior to intravenous amivantamab with lazertinib in terms of efficacy in treating refractory ...